NCT07432594 2026-02-25
Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
Clinical Trials
20 trialsNCT03776812 2025-10-07
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Corcept Therapeutics
Phase 2 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04680988 2025-08-05
A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT05983276 2024-02-08
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
Loyola University
Phase 2 Recruiting
NCT06055738 2023-09-28
Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC
Tang-Du Hospital
Phase 2 Recruiting
NCT05310344 2022-04-04
Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05290935 2022-03-22
Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04188860 2022-03-15
Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy
Peking Union Medical College Hospital
Phase 2 Completed
NCT04815408 2021-03-25
PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT04590625 2020-10-19
Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer
Zhongshan Hospital Xiamen University
Phase 2 Unknown
NCT03942068 2019-05-08
Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT00309959 2019-01-08
ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer
GOG Foundation
Phase 2 Completed
NCT00499252 2018-01-11
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT00585052 2018-01-05
A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer
University of Iowa
Phase 2 Terminated
NCT00466960 2017-08-28
Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy
University of Washington
Phase 2 Completed
NCT01821859 2013-07-26
Abraxane/Bevacizumab
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT01667211 2012-08-22
CSAPPPCC
ChineseAMS
Phase 2 Unknown
NCT00407563 2012-04-05
Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer
Accelerated Community Oncology Research Network
Phase 2 Completed
NCT00466986 2011-10-12
Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer
Southeastern Gynecologic Oncology
Phase 2 Completed